$0.43
-0.05 (-10.31%)
Open$0.47
Previous Close$0.48
Day High$0.50
Day Low$0.43
52W High$3.15
52W Low$0.46
Volume—
Avg Volume58.5K
Market Cap20.92M
P/E Ratio—
EPS$-0.25
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,395.6% upside
Current
$0.43
$0.43
Target
$15.08
$15.08
$11.92
$15.08 avg
$19.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.42M | 17.19M | 14.45M |
| Net Income | 959.9K | 1.03M | 875.1K |
| Profit Margin | 5.2% | 6.0% | 6.1% |
| EBITDA | 1.74M | 1.49M | 1.43M |
| Free Cash Flow | 993.5K | 1.08M | 606.8K |
| Rev Growth | +1.0% | +13.6% | +14.7% |
| Debt/Equity | 0.15 | 0.16 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |